Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2012-03-31 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于大华会计师事务所有限公司改制的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the restructuring of its auditing firm from DaHua CPA Co., Ltd. to DaHua CPA (Special General Partnership). It mentions a board resolution to change the 2011 financial statement auditor and plans to submit this change to the 2012 first extraordinary shareholders meeting. The document is short (754 characters) and serves as a formal notice about the auditor change and related procedural matters. It does not contain financial statements, audit reports, or detailed financial data. It is not a full audit report or annual report but an announcement related to audit firm changes. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2012-03-31 Chinese
2011年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a '2011年度业绩快报' which translates to '2011 Annual Performance Express Report' or '2011 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2011, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary and unaudited by an accounting firm, indicating it is a quick earnings summary rather than a full audited annual report. The length of the document is about 2062 characters, which is relatively short and consistent with an earnings release rather than a full annual report. There is no indication that this is a full annual report (10-K) or audit report (AR). The document is not a notice or announcement of a report publication but the report itself, albeit preliminary. Therefore, the best classification is Earnings Release (ER). FY 2011
2012-02-20 Chinese
关于对控股子公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the capital increase (增资) in a controlling subsidiary by the parent company. It details the amount of capital injection, the board approval, related party transactions, and the impact on the company. The document is relatively short (2176 characters) and focuses on a financing event involving equity capital increase in a subsidiary. It is not a full financial report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it concerns updates on company fundraising and capital structure changes through equity injection into a subsidiary.
2012-02-09 Chinese
第四届董事会第二十六次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Beijing Shuanglu Pharmaceutical Co., Ltd. It details the decision made at the 26th interim meeting of the 4th board of directors regarding capital increase to a subsidiary. The document includes specifics about the meeting date, voting results, and the capital increase amount. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an announcement of a board decision related to capital financing but not a direct capital/financing update filing like a financing transaction or fundraising announcement. The document is best classified as Board/Management Information (MANG) because it reports on a board meeting resolution and related corporate governance matters.
2012-02-09 Chinese
独立董事关于公司对控股子公司增资的独立意见
Capital/Financing Update Classification · 90% confidence The document is an independent director's opinion on the company's capital increase in a controlled subsidiary. It discusses the board meeting resolution, the amount of capital increase, and the independent directors' review and approval of the transaction. There are no financial statements, no quarterly or annual report data, no earnings highlights, and no regulatory certifications. The document is a formal opinion related to a specific corporate action (capital increase) but does not constitute a full capital/financing update report. It is not a report publication announcement or a regulatory filing. Given the content, it best fits under the category of Capital/Financing Update (CAP), as it relates to the company's financing activity involving capital injection into a subsidiary.
2012-02-09 Chinese
独立董事关于对外（境外）投资的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent opinion from the independent directors of Beijing SL Pharmaceutical Co., Ltd. regarding an external (overseas) investment proposal. It discusses the approval of an investment to establish a joint venture in Delaware, USA, and assesses the impact and compliance of this investment. The document is not a full financial report, audit, or earnings release, nor is it a regulatory filing or announcement of voting results. It is a formal opinion related to a specific corporate action (investment decision) by the board, but it does not announce management changes or capital structure changes. Given the nature of the document as an independent directors' opinion on a corporate investment matter, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-12-16 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.